Invion Limited

University of Houston System

Egb Advisors, LLC

Inverseon, Inc.

Richard A Bond

Burton F Dickey

Michael J Tuvim

Mitchell Glass

The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.

Use of beta-adrenergic inverse agonists for smoking cessation

Provided herein is a pharmaceutical composition combination which comprises (a) a corticosteroid and (b) b-adrenergic receptor antagonist characterised in that active ingredients (a) and (b) form part of a single composition. Further provided is a method of treating a human or animal patient suffering from or susceptible to a respiratory disease or condition, said method comprises simultaneously, concurrently, separately or sequentially administering to the patient an effective amount of a b-adrenergic receptor antagonist and a corticosteroid.

Steroid-sparing effects of beta-adrenergic inverse agonists and uses thereof

The use of &#x3b2;-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a &#x3b2;-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol.

Method of treating airway diseases with &#x3b2;-adrenergic inverse agonists

The use of &#x3b2;-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method involves administering a therapeutically effective amount of a &#x3b2;-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol. In addition, methods are described for long-tern administration of such inverse agonists and for determining the suitability of patients for long-term inverse agonist therapy.

Growing community of inventors

Houston, TX, United States of America

Richard A Bond